Deals
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
FEATURED STORIES
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
The SEC said that Yum China, BeiGene, Zai Lab, HutchMed and ACM Research are all at risk if they do not give U.S. regulators access to their audit records.
Gilead Sciences is letting go of 114 employees following an underwhelming response to the results reaped so far from its $21 billion acquisition of Immunomedics in 2020.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.
The European Commission has provided an update that it remains unconvinced by the merger, which spells bad news for Illumina.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Shares of Adagene Inc. are up more than 10% in premarket trading after the company announced a monoclonal and bispecific antibody collaboration with Sanofi valued at up to $2.5 billion.
AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion.
Biocon Biologics has acquired its partner Viatris’ biosimilars assets. The transaction is part of an effort to create a global, vertically-integrated biosimilars leader.